20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer.

Publication Dbxref
PMID:28881818
Title
20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer.
Publication Type
Journal Article
Series Name
Oncotarget
Volume
8
Publication Year
2017
Issue
32
Page Numbers
53375-53386
DOI
10.18632/oncotarget.18482
Journal Abbreviation
Oncotarget
EISSN
1949-2553
Publication Date
2017 Aug 08
Citation
Li J, Lu J, Ye Z, Han X, Zheng X, Hou H, Chen W, Li X, Zhao L. 20(S)-Rg3 blocked epithelial-mesenchymal transition through DNMT3A/miR-145/FSCN1 in ovarian cancer.. Oncotarget. 2017 Aug 08; 8(32):53375-53386.
ISSN
1949-2553
Language Abbr
eng
Publication Model
Electronic-eCollection
Authors
Li J, Lu J, Ye Z, Han X, Zheng X, Hou H, Chen W, Li X, Zhao L
Language
English
Elocation
10.18632/oncotarget.18482
Journal Country
United States
Abstract

Epithelial-mesenchymal transition (EMT) is one of the key mechanisms mediating cancer progression. MicroRNAs (miRs) are essential regulators of gene expression by suppressing translation or causing degradation of target mRNA. Growing evidence illustrates the crucial roles of miRs dysregulation in cancer development and progression. Here, we have found for the first time that the ginsenoside 20(S)-Rg3, a pharmacologically active component of Panax ginseng, potently increases miR-145 expression by downregulating methyltransferase DNMT3A to attenuate the hypermethylation of the promoter region in the miR-145 precursor gene. Restoration of DNMT3A reverses the inhibitory effect of 20(S)-Rg3 on EMT. FSCN1 is verified as the target of miR-145 to suppress EMT in human ovarian cancer cells. The results from nude mouse xenograft models further demonstrate the suppressive effect of miR-145 on malignant progression of ovarian cancer. Taken together, our results show that 20(S)-Rg3 blocks EMT by targeting DNMT3A/miR-145/FSCN1 pathway in ovarian cancer cells, highlighting the potentiality of 20(S)-Rg3 to be used as a therapeutic agent for ovarian cancer.

Database Reference Annotations
Is Obsolete
False